145 related articles for article (PubMed ID: 15203171)
1. Design, synthesis, and evaluation of estradiol-linked genotoxicants as anti-cancer agents.
Sharma U; Marquis JC; Nicole Dinaut A; Hillier SM; Fedeles B; Rye PT; Essigmann JM; Croy RG
Bioorg Med Chem Lett; 2004 Jul; 14(14):3829-33. PubMed ID: 15203171
[TBL] [Abstract][Full Text] [Related]
2. A rationally designed genotoxin that selectively destroys estrogen receptor-positive breast cancer cells.
Mitra K; Marquis JC; Hillier SM; Rye PT; Zayas B; Lee AS; Essigmann JM; Croy RG
J Am Chem Soc; 2002 Mar; 124(9):1862-3. PubMed ID: 11866593
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological activity of DNA damaging agents that form decoy binding sites for the estrogen receptor.
Rink SM; Yarema KJ; Solomon MS; Paige LA; Tadayoni-Rebek BM; Essigmann JM; Croy RG
Proc Natl Acad Sci U S A; 1996 Dec; 93(26):15063-8. PubMed ID: 8986764
[TBL] [Abstract][Full Text] [Related]
4. A bifunctional platinum(II) antitumor agent that forms DNA adducts with affinity for the estrogen receptor.
Kim E; Rye PT; Essigmann JM; Croy RG
J Inorg Biochem; 2009 Feb; 103(2):256-61. PubMed ID: 19054566
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, characterization, and cytotoxicity of a series of estrogen-tethered platinum(IV) complexes.
Barnes KR; Kutikov A; Lippard SJ
Chem Biol; 2004 Apr; 11(4):557-64. PubMed ID: 15123250
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and biological evaluation of ellipticine-estradiol conjugates.
Devraj R; Barrett JF; Fernandez JA; Katzenellenbogen JA; Cushman M
J Med Chem; 1996 Aug; 39(17):3367-74. PubMed ID: 8765520
[TBL] [Abstract][Full Text] [Related]
7. DNA minor groove targeted alkylating agents based on bisbenzimidazole carriers: synthesis, cytotoxicity and sequence-specificity of DNA alkylation.
Smaill JB; Fan JY; Denny WA
Anticancer Drug Des; 1998 Dec; 13(8):857-80. PubMed ID: 10335264
[TBL] [Abstract][Full Text] [Related]
8. Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT).
Springer CJ; Dowell R; Burke PJ; Hadley E; Davis DH; Blakey DC; Melton RG; Niculescu-Duvaz I
J Med Chem; 1995 Dec; 38(26):5051-65. PubMed ID: 8544182
[TBL] [Abstract][Full Text] [Related]
9. Self-immolative nitrogen mustard prodrugs for suicide gene therapy.
Niculescu-Duvaz D; Niculescu-Duvaz I; Friedlos F; Martin J; Spooner R; Davies L; Marais R; Springer CJ
J Med Chem; 1998 Dec; 41(26):5297-309. PubMed ID: 9857097
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of novel benzothiophene analogs as selective estrogen receptor covalent antagonists against breast cancer.
Bai C; Ren S; Wu S; Zhu M; Luo G; Xiang H
Eur J Med Chem; 2021 Oct; 221():113543. PubMed ID: 34022716
[TBL] [Abstract][Full Text] [Related]
11. Design of novel tyrosine-nitrogen mustard hybrid molecules active against uterine, ovarian and breast cancer cell lines.
Descôteaux C; Brasseur K; Leblanc V; Parent S; Asselin E; Bérubé G
Steroids; 2012 Apr; 77(5):403-12. PubMed ID: 22227028
[TBL] [Abstract][Full Text] [Related]
12. A metastatic breast tumor cell line, GI-101A, is estrogen receptor positive and responsive to estrogen but resistant to tamoxifen.
Morrissey JJ; Raney S
Cell Biol Int; 1998; 22(6):413-9. PubMed ID: 10328849
[TBL] [Abstract][Full Text] [Related]
13. Potent antitumor 9-anilinoacridines and acridines bearing an alkylating N-mustard residue on the acridine chromophore: synthesis and biological activity.
Su TL; Lin YW; Chou TC; Zhang X; Bacherikov VA; Chen CH; Liu LF; Tsai TJ
J Med Chem; 2006 Jun; 49(12):3710-8. PubMed ID: 16759114
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and estrogen receptor binding affinity of a porphyrin-estradiol conjugate for targeted photodynamic therapy of cancer.
James DA; Swamy N; Paz N; Hanson RN; Ray R
Bioorg Med Chem Lett; 1999 Aug; 9(16):2379-84. PubMed ID: 10476873
[TBL] [Abstract][Full Text] [Related]
15. Use of dong quai (Angelica sinensis) to treat peri- or postmenopausal symptoms in women with breast cancer: is it appropriate?
Lau CB; Ho TC; Chan TW; Kim SC
Menopause; 2005; 12(6):734-40. PubMed ID: 16278617
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, cytocidal activity and estrogen receptor α affinity of doxorubicin conjugates at 16α-position of estrogen for site-specific treatment of estrogen receptor positive breast cancer.
Saha P; Fortin S; Leblanc V; Parent S; Asselin É; Bérubé G
Steroids; 2012 Sep; 77(11):1113-22. PubMed ID: 22801351
[TBL] [Abstract][Full Text] [Related]
17. Steroidal affinity labels of the estrogen receptor. 3. Estradiol 11 beta-n-alkyl derivatives bearing a terminal electrophilic group: antiestrogenic and cytotoxic properties.
Lobaccaro C; Pons JF; Duchesne MJ; Auzou G; Pons M; Nique F; Teutsch G; Borgna JL
J Med Chem; 1997 Jul; 40(14):2217-27. PubMed ID: 9216841
[TBL] [Abstract][Full Text] [Related]
18. 1alpha,25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells.
Swami S; Krishnan AV; Feldman D
Clin Cancer Res; 2000 Aug; 6(8):3371-9. PubMed ID: 10955825
[TBL] [Abstract][Full Text] [Related]
19. The synthesis and biological evaluation of new DNA-directed alkylating agents, phenyl N-mustard-4-anilinoquinoline conjugates containing a urea linker.
Marvania B; Kakadiya R; Christian W; Chen TL; Wu MH; Suman S; Tala K; Lee TC; Shah A; Su TL
Eur J Med Chem; 2014 Aug; 83():695-708. PubMed ID: 25014640
[TBL] [Abstract][Full Text] [Related]
20. Chemical genetics analysis of an aniline mustard anticancer agent reveals complex I of the electron transport chain as a target.
Fedeles BI; Zhu AY; Young KS; Hillier SM; Proffitt KD; Essigmann JM; Croy RG
J Biol Chem; 2011 Sep; 286(39):33910-20. PubMed ID: 21832047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
